Director Mark Steven Davis filed a Form 4 with the SEC on November 19, 2026, disclosing the sale of 6,100 shares of Myriad Genetics Inc common stock on November 18, 2026.
Key Highlights
- Reporting person: Mark Steven Davis, identified as a Director of Myriad Genetics Inc (NASDAQ:MYGN)
- Transaction: Disposition of 6,100 shares of common stock on November 18, 2026
- Price: Shares sold at $5.615 each, according to the filing
- Post-transaction ownership: Davis beneficially owned 100,565 shares directly following the transaction
- Transaction code: "S" (sale), reported as a direct ownership form
- Filing signed: By Justin Hunter on behalf of Mark S. Davis, dated November 19, 2026
Davis Reduces Direct Holdings in Myriad Genetics by 6,100 Shares
According to the Form 4 filed with the SEC, Mark Steven Davis, a Director of Myriad Genetics Inc, disposed of 6,100 shares of the company's common stock on November 18, 2026, at a price of $5.615 per share. The transaction is coded "S," indicating an open-market sale, and the ownership form is listed as direct.
Following the reported transaction, Davis held 100,565 shares of Myriad Genetics common stock directly, as disclosed in the filing. No derivative securities transactions were reported in Table II of the form. The filing does not indicate whether the transaction was made pursuant to a Rule 10b5-1 trading plan, as that check box was not selected on the form.
The Form 4 was filed on November 19, 2026, the day after the transaction date. The form was signed by Justin Hunter acting on behalf of Mark S. Davis. No amendment date was listed, indicating this is an original filing. Davis's address is listed as 322 North 2200 West, Salt Lake City, Utah 84116, according to the filing.
What Was Disclosed
A Myriad Genetics director reported a sale of 6,100 shares of common stock at $5.615 per share on November 18, 2026, leaving him with a directly held beneficial ownership of 100,565 shares following the transaction.



Please wait processing your request...